<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158170">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031393</url>
  </required_header>
  <id_info>
    <org_study_id>217/13</org_study_id>
    <nct_id>NCT02031393</nct_id>
  </id_info>
  <brief_title>Establishing First Trimester Markers for the Identification of High Risk Twin</brief_title>
  <official_title>Establishing First Trimester Sonographic, Biochemical and Clinical Markers for the Identification of High Risk Twin in the First Trimester</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether we can establish different markers suc as
      mean arterial pressure , flow in the uterine arteries, biochemical markers in maternal blood
      and more un the first trimester, in order to screen for twin pregnancies that are more
      likely to develop adverse pregnancy outcome: early delivery, pre eclampsia or small fetuses.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>The development  of preeclampsia</measure>
    <time_frame>after delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>the women will be approached after birth to asses whether they developed preeclampsia or pregnancy induced hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intra uterine growth restriction</measure>
    <time_frame>after delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Small for Gestational Age (Disorder)</condition>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>singelton pregnancy</arm_group_label>
    <description>will be followed 11-14 weeks and 19-28 weeks of gestation and after birth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>twin pregnancy</arm_group_label>
    <description>will be followed 11-14 weeks and 19-28 weeks of gestation and after birth</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women that will come to our first trimester clinic inorder to preform first
        trimester screeninig
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women from 11 -14 weeks of gestation

        Exclusion Criteria:

          -  nuchal thickness above 3 mm,

          -  Chronic hypertension,

          -  thrombophilia,

          -  Diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assaf Harofe obstetric department</name>
      <address>
        <city>Be'er Ya`aqov</city>
        <state>Zrifin</state>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
